PDS BIOTECHNOLOGY ($PDSB) posted quarterly earnings results for Q1 2026 on Wednesday, May 13th. The company reported earnings of -$0.13 per share, beating estimates of -$0.15 by $0.02. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $PDSB stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
PDS BIOTECHNOLOGY Hedge Fund Activity
We have seen 16 institutional investors add shares of PDS BIOTECHNOLOGY stock to their portfolio, and 25 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC added 2,834,506 shares (+inf%) to their portfolio in Q4 2025, for an estimated $2,182,002
- CITADEL ADVISORS LLC removed 386,430 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $297,473
- UBS GROUP AG removed 195,701 shares (-77.8%) from their portfolio in Q1 2026, for an estimated $118,399
- COMMONWEALTH EQUITY SERVICES, LLC removed 106,000 shares (-53.9%) from their portfolio in Q1 2026, for an estimated $64,130
- RENAISSANCE TECHNOLOGIES LLC removed 99,161 shares (-35.9%) from their portfolio in Q4 2025, for an estimated $76,334
- SQUAREPOINT OPS LLC removed 99,071 shares (-34.0%) from their portfolio in Q4 2025, for an estimated $76,264
- ACADIAN ASSET MANAGEMENT LLC removed 61,793 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $47,568
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
PDS BIOTECHNOLOGY Analyst Ratings
Wall Street analysts have issued reports on $PDSB in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B. Riley Securities issued a "Buy" rating on 11/25/2025
To track analyst ratings and price targets for PDS BIOTECHNOLOGY, check out Quiver Quantitative's $PDSB forecast page.
PDS BIOTECHNOLOGY Price Targets
Multiple analysts have issued price targets for $PDSB recently. We have seen 2 analysts offer price targets for $PDSB in the last 6 months, with a median target of $9.0.
Here are some recent targets:
- Joseph Pantginis from HC Wainwright & Co. set a target price of $15.0 on 04/15/2026
- Kalpit Patel from B. Riley Securities set a target price of $3.0 on 11/25/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
